Klin Farmakol Farm. 2020;34(2):47-55 | DOI: 10.36290/far.2020.011

Therapeutic drug monitoring

Ivana Kacířová1,2, Milan Grundmann2
1 Oddělení klinické farmakologie, Ústav laboratorní diagnostiky, Fakultní nemocnice Ostrava
2 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita, Ostrava

Therapeutic drug monitoring is a specific method of clinical pharmacology for monitoring of pharmacotherapy using measurement of drug serum concentrations followed by erudite interpretation. The concept of the method rests on the assumption that clinical effect correlates better with drug concentration than with the dose. We would like to present informations relating to utilization of therapeutic drug monitoring method in routine clinical practice.

Keywords: clinical pharmacology, therapeutic drug monitoring, drug concentration.

Published: July 16, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kacířová I, Grundmann M. Therapeutic drug monitoring. Klin Farmakol Farm. 2020;34(2):47-55. doi: 10.36290/far.2020.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013; 69(1): 25-32. Go to original source...
    2. Grundmann M, Kacířová I. Význam TDM, fenotypizace a genotypizace pro správné dávkování léčiv. Čas Lék čes 2010; 149: 482-487.
    3. Dave V, Yadav RB, Yadav S, Sharma S, Sahu RK, Ajayi AF. A critique of computer simulation software's used in pharmacokinetics and pharmacodynamics analysis. Curr Clin Pharmacol 2018; 13(4): 216-235. Go to original source... Go to PubMed...
    4. Kacířová I, Grundmann M. TDM antibiotik v klinické praxi. Kardiol Rev Int Med 2015; 17(1): 57-64.
    5. Kacířová I, Grundmann M. Terapeutické monitorování amikacinu a gentamicinu v rutinní klinické praxi. Vnitř Lék 2015; 61(1): 33-41. Go to PubMed...
    6. Abdul‑Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper [published online ahead of print, 2020 May 7]. Intensive Care Med 2020; 1-27.
    7. Suchánková H, Matušková Z, Vanduchová A. Terapeutické monitorování beta‑laktamových antibiotik. Klin mikrobiol inf lék 2017; 23(1): 4-9.
    8. Ben Romdhane H, Ben Fredj N, Chaabane A, et al. Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrol Ther 2019; 15(2): 110-114. Go to original source...
    9. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti‑pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations:V. Aminoglycosides. Pediatr Pulmonol 2013; 48: 1047-1061. Go to original source... Go to PubMed...
    10. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41(6): 441-449. Go to original source... Go to PubMed...
    11. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99. Go to original source...
    12. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013; 36(4): 217-230. Go to original source...
    13. Alqahtani S, Alhumoud A, Abushomi H, Alsultan A, Balkhi B. Appropriate therapeutic drug monitoring of antibiotics contributed to lower nephrotoxicity. Int J Clin Pharmacol Ther 2020 Feb; 58(2): 82-88. Go to original source...
    14. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63(5): 1050-1057. Go to original source... Go to PubMed...
    15. Moise‑Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-942. Go to original source...
    16. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health‑System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49(3): 325-327. Go to original source... Go to PubMed...
    17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‑resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011; 52(3): 285-292. Go to original source... Go to PubMed...
    18. Helgason KO, Thomson AH, Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008; 61(6): 1398-1399. Go to original source... Go to PubMed...
    19. Abdul‑Aziz MH, Lipman J, Roberts JA. Identifying "at‑risk" patients for sub‑optimal beta‑lactam exposure in critically ill patients with severe infections. Crit Care 2017; 21: 21(1): 283. Go to original source...
    20. Roberts JA, Paul SK, Akova M, et al. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β‑Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clin Infect Dis 2014; 58(8): 1072-1083. Go to original source... Go to PubMed...
    21. Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β‑lactams treatment in critically‑ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther 2017; 15(7): 677-688. Go to original source... Go to PubMed...
    22. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit 2018; 40(5): 526-548. Go to original source... Go to PubMed...
    23. Grundmann M, Kacířová I. Terapeutické monitorování hladin antiepileptik I. - obecné zásady, "stará" antiepileptika. Klin Farmakol Farm 2016; 30(2): 9-15. Go to original source...
    24. Kacířová I, Grundmann M. Terapeutické monitorování hladin antiepileptik II. - "nová" antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16-22. Go to original source...
    25. Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther 2018; 12: 271-280. Go to original source... Go to PubMed...
    26. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1-02): 9-62. Go to original source... Go to PubMed...
    27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533. Go to original source...
    28. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878. Go to original source...
    29. Ahmed A, Waagstein F, Pitt B, et al. Effectiveness of digoxin in reducing one‑year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol 2009; 103(1): 82-87. Go to original source...
    30. Grundmann M, Kacířová I. Personalizovaná farmakoterapie digoxinem. Vnitř Lék 2015; 61(5): 406-409. Go to PubMed...
    31. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018; 13; 71(10): 1063-1074. Go to original source...
    32. Moffett BS, Garner A, Zapata T, Orcutt J, Niu M, Lopez KN. Serum digoxin concentrations and clinical signs and symptoms of digoxin toxicity in the paediatric population. Cardiol Young 2016; 26: 498-493. Go to original source...
    33. Park M. Congestive heart failure. In: Park MK, (ed) Pediatric Cardiology for Practitioners, (4th ed) St Louis: Mosby; 2002: 403-406.
    34. Gabarin N, Jaeggi ET, Spears DA, Sermer M, Silversides CK, Bhagra CJ. Concurrent maternal and fetal tachyarrhythmia in pregnancy. Obstet Med 2017; 10(4): 195-197. Go to original source... Go to PubMed...
    35. Grundmann M, Koristkova B, Brozmanova H, Kacirova I, Komzakova I. The interaction between digoxin and amiodarone during routine TDM. Ther Drug Monit 2005; 27(2): 219-220. Go to original source...
    36. Hrudikova Vyskocilova E, Grundmann M, Duricova J, Kacirova I. Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017 Jun; 161(2): 134-143. Go to original source... Go to PubMed...
    37. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 2017 Dec; 45(6): 737-779. Go to original source... Go to PubMed...
    38. Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother 2017; 72: i12-i18. Go to original source... Go to PubMed...
    39. Ullmann AJ, Aguado JM, Arikan‑Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID‑ECMM‑ERS guideline. Clin Microbiol Infect 2018 May; 24 Suppl 1: e1-e38. Go to original source...
    40. Arendrup MC, Cuenca‑Estrella M, Lass‑Flörl C, Hope WW. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST‑AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 18: E248-250. Go to original source... Go to PubMed...
    41. Yi WM, Schoeppler KE, Jaeger J, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017 Sep 11; 16(1): 60. Go to original source... Go to PubMed...
    42. Shuker N, van Gelder T, Hesselink DA. Intra‑patient variability in tacrolimus exposure: Causes, consequences for clinical management. Transplant Rev (Orlando) 2015; 29: 78-84. Go to original source... Go to PubMed...
    43. Snanoudj R, Rabant M, Royal V, Pallet N, Noel LH, Legendre C. Nephrotoxicite des inhibiteurs de la calcineurine: presentation, problemes diagnostiques et facteurs de risques (Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors). Nephrol Ther 2009; 5(Suppl 6): S365-370. Go to original source...
    44. del Mar Fernandez De Gatta M, Santos‑Buelga D, Dominguez‑Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41(2): 115-135. Go to original source...
    45. Viklický O. Imunosuprese po transplantaci ledviny. Klinická farmakologie a farmacie. 2010; 24(2): 98-102.
    46. Konsenzus IKEM; https://www2.ikem.cz/plm_lp/HVEZDAADCG.htm; 6. 2. 2020.
    47. Teřl M, Čáp P, Dvořáková R, et al. Doporučený postup diagnostiky a léčby bronchiálního astmatu. Semily: GEUM; 2015.
    48. http://www.sukl.cz/modules/medication/search.php; 4. 2. 2020.
    49. Cooney L, Hawcutt D, Sinha I. The Evidence for Intravenous Theophylline Levels between 10-20 mg/L in Children Suffering an Acute Exacerbation of Asthma: A Systematic Review. PLoS One 2016 Apr 20; 11(4): e0153877. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.